NCT06238401
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 29, 2024
Completion: Jan 1, 2026